What is the maximum dose of norepinephrine (vasopressor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Dose of Norepinephrine in Vasopressor Therapy

There is no absolute maximum dose of norepinephrine for vasopressor therapy; instead, norepinephrine should be titrated based on clinical response with doses typically ranging from 0.1-3.0 mg/hour (approximately 0.01-3.0 μg/kg/min), with higher doses used in refractory cases.

Dosing Guidelines and Classifications

  • Norepinephrine is typically administered as a continuous IV infusion starting at 0.5 mg/hour and increased by 0.5 mg/hour every 4 hours to a maximum of 3.0 mg/hour, with the goal of increasing mean arterial pressure (MAP) by 10 mmHg or achieving adequate urine output (>50 mL/h) 1
  • For clinical categorization of vasopressor support, norepinephrine doses can be classified as 2:
    • Low dose: <0.2 μg/kg/min
    • Intermediate dose: 0.2-0.4 μg/kg/min
    • High dose: >0.4 μg/kg/min

Clinical Endpoints and Titration

  • The primary goal of norepinephrine therapy is to achieve and maintain a target MAP, typically 65 mmHg in most patients with septic shock 1
  • Doses should be titrated to the minimum effective dose that achieves the desired clinical endpoints 1, 3:
    • Adequate MAP (≥65 mmHg)
    • Improved tissue perfusion
    • Adequate urine output
    • Decreasing lactate levels

Special Considerations for High Doses

  • Doses ≥0.6 μg/kg/min within the first 24 hours of ICU admission are associated with significantly higher 7-day mortality (sensitivity 47%, specificity 93%) and may indicate refractory septic shock 4
  • When high doses are required, consider adding a second vasopressor agent such as epinephrine or vasopressin rather than continuing to escalate norepinephrine 1
  • Vasopressin (up to 0.03 U/min) can be added to norepinephrine to either raise MAP to target or to decrease the required norepinephrine dose 1

Pediatric Dosing

  • For pediatric patients, norepinephrine dosing typically ranges from 0.1-1.0 μg/kg/minute 5
  • In severe cases, doses as high as 5 μg/kg/minute may be necessary in children 5
  • The "rule of 6" can be used for pediatric dosing: 0.6 × body weight (kg) = number of milligrams diluted to total 100 mL of saline; then 1 mL/h delivers 0.1 μg/kg/min 5

Monitoring and Safety Considerations

  • Continuous hemodynamic monitoring is essential during norepinephrine administration 3
  • Avoid mixing norepinephrine solutions with alkali-labile drugs due to compatibility concerns 6
  • For extravasation, phentolamine (0.1-0.2 mg/kg up to 10 mg diluted in 10 mL of 0.9% sodium chloride) should be injected intradermally at the extravasation site to counteract dermal vasoconstriction 5
  • Monitor for signs of excessive vasoconstriction, which may compromise tissue perfusion 3, 7

Weaning Strategy

  • Once hemodynamic stability is achieved, vasopressors should be weaned gradually while continuing fluid resuscitation as needed 1
  • Prioritize weaning vasopressors with continuing fluid resuscitation when adequate tissue perfusion is restored 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Norepinephrine Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Aminophylline Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.